Nexalin Technology (NXL) announced that its Gen-2 Console, SYNC, 15 milliamp neurostimulation device has been granted regulatory approval for sale in Israel by the Israeli Ministry of Health. Mark White, CEO of Nexalin Technology, stated, “We are extremely proud to have received regulatory clearance in Israel, which is recognized worldwide for its rigorous and highly respected health regulatory standards. This approval is an important milestone that not only allows us to introduce our innovative, drug-free technology to patients and providers in Israel but also strengthens the global credibility of our platform as we pursue additional international markets. Globally, this builds on our prior approvals in China, Brazil and Oman. This recent approval in Israel directly supports our strategy to aggressively expand our presence across the region.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NXL:
- Nexalin announces three studies published on Gen-2 Nexalin DIFS technology
- Nexalin Technology Amends Equity Distribution Agreement
- Nexalin Technology appoints Robert Rothstein to Scientific Advisory Board
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- 3 Penny Stocks to Watch Now, 10/9/25